Efficacy of Iodine Complex Against COVID-19 Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 30
Summary
- Conditions
- Corona Virus Infection
- COVID-19
- Sars Cov 2
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Randomized, controlled, multi-armed, close-label, interventional study designedMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: empty capsule will be given as a placeboPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The proposed study is a placebo-controlled, add-on, randomized trial using parallel group designs. This is a close-label and adaptive, multi-centered design with 1:1:1:1 allocation ratio and superiority framework.
The proposed study is a placebo-controlled, add-on, randomized trial using parallel group designs. This is a close-label and adaptive, multi-centered design with 1:1:1:1 allocation ratio and superiority framework.
Tracking Information
- NCT #
- NCT04473261
- Collaborators
- Not Provided
- Investigators
- Study Chair: Muhammad Ashraf, PhD University of Veterinary & Animal Sciences, Pakistan Study Director: Shoaib Ashraf, PhD Harvard University, Massachusetts General Hospital, Boston, USA Principal Investigator: Moneeb Ashraf, MBBS Mayo Hospital, Pakistan Principal Investigator: Sohaib Ashraf, MBBS Shaikh Zayed Medical Complex, Pakistan
Get Well Soon